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Abstract
Background: Despite the high global prevalence of prostate cancer (PCa), few epidemi-
ologic studies have assessed physical activity in relation to PCa survival.
Objective: To evaluate different types, intensities, and timing of physical activity rela-
tive to PCa survival.
Design, setting, and participants: A prospective studywas conducted in Alberta, Canada,
in a cohort of 830 stage II–IV incident PCa cases diagnosed between 1997 and 2000 with
follow-up to 2014 (up to 17 yr). Prediagnosis lifetime activity was self-reported at
diagnosis. Postdiagnosis activity was self-reported up to three times during follow-up.
Outcome measurements and statistical analysis: Cox proportional hazards models
related physical activity to all-cause and PCa-speciﬁc deaths and to ﬁrst recurrence/
progression of PCa.
Results and limitations: A total of 458 deaths, 170 PCa-speciﬁc deaths, and, after ﬁrst
follow-up, 239 ﬁrst recurrences/progressions occurred. Postdiagnosis total activity
(>119 vs 42 metabolic equivalent [MET]-hours/week per year) was associated with a
signiﬁcantly lower all-cause mortality risk (hazard ratio [HR]: 0.58; 95% conﬁdence
interval [CI], 0.42–0.79; p value for trend <0.01). Postdiagnosis recreational activity
(>26 vs 4 MET-hours/week per year) was associated with a signiﬁcantly lower PCa-
speciﬁc mortality risk (HR: 0.56; 95% CI, 0.35–0.90; p value for trend = 0.01). Sustained
recreational activity before and after diagnosis (>18–20 vs <7–8 MET-hours/week per
year)was associatedwith a lower risk of all-causemortality (HR: 0.66; 95% CI, 0.49–0.88).
Limitations included generalisability to healthier cases and an observational study design.
Conclusions: These ﬁndings support emerging recommendations to increase physical
activity after the diagnosis of PCa and would inform a future exercise intervention trial
examining PCa outcomes.
Patient summary: In a 17-yr prostate cancer (PCa) survival study, men who survived at
least 2 yr who were more physically active postdiagnosis or performed more recrea-
tional physical activity before and after diagnosis survived longer. Recreational physical
activity after diagnosis was associated with a lower risk of PCa death.
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In Canada, 5-yr survival fromprostate cancer (PCa) is high at
81%, yet 1 in 27 men will die from PCa [1]. Worldwide in
2012, an estimated 1.1 million new PCa cases were
diagnosed [2]. Given the high disease burden, there is clear
interest in identifying inexpensive, noninvasive strategies
for improving PCa survival.
Three studies have assessed associations between post-
diagnosis physical activity and PCa progression or survival
[3–5]. Kenfield et al [3] evaluated postdiagnosis activity in
2705 PCa cases over 9.7 yr on average. Risk of PCa-specific
death was significantly 61% lower for men reporting
3 versus <1 h per week vigorous activity. Furthermore,
men who maintained the highest versus lowest level of
vigorous activity pre- and postdiagnosis experienced a
nonsignificant 60% lower PCa mortality risk. In the second
study [4], 1455menwith localised PCawere followed 22mo
on average. Men who walked briskly 3 versus <3 h per
weekhada57%significantly lower riskofprogression.A third
study [5] followed 4623 localised PCa survivors up to 15 yr.
Postdiagnosis moderate walking/bicycling 20 versus
<20min per day and moderate-vigorous exercise1 versus
<1 h per week were associated with 39% and 32% signifi-
cantly lower risks of PCa mortality, respectively.
Given limited epidemiologic evidence relating physical
activity to survival, we conducted a prospective cohort
study of PCa survivors in Alberta, Canada, to identify all
deaths and first recurrences/progressions of PCa. We aimed
to evaluate the type, intensity, and timing of activity
associated with survival, the role of occupational sedentary
behaviour, and associations with physical activity changes
across the diagnostic period. We hypothesised that men
who were more active before and after diagnosis would
survive longer. Our goal was to inform a potential phase
3 trial on this question as well as clinical recommendations
for survivors.
2. Patients and methods
2.1. Participants
Caseswere participants in a case-control study [6], and subsequently our
case-only survival analysis, who resided in Alberta with incident,
histologically conﬁrmed, clinically signiﬁcant stage II–IV invasive PCa.
Incident cases were identiﬁed through the Alberta Cancer Registry (ACR)
from 1997 to 2000. Eligibility included no previous cancer except
nonmelanoma skin cancer, English speaking, Alberta resident, not
physician excluded, and age <80 yr. Permission to contact patients was
sought through referring physicians. The case-control study received
ethics approval from the former Alberta Cancer Board (ACB) and the
University of Calgary. All cases provided written informed consent for
the cohort study, beginning in 2000, and to recontact their physicians for
missing medical data.
2.2. Data collection
2.2.1. Prediagnosis lifestyle
In-person interviews on lifetime physical activity were completed on
average 4.3 mo (standard deviation: 1.3) after diagnosis. The LifetimeTotal Physical Activity Questionnaire (LTPAQ) [7] was administered
using cognitive interviewing methods and a recall calendar to assess the
frequency, duration, and intensity of occupational, household, and
recreational activities from childhood until diagnosis (Supplement 1).
Each respondent reported demographic and personal health informa-
tion, PCa screening history, prostate conditions/surgeries, family history
of cancer, lifetime smoking, and alcohol consumption. Participants
reported their usual diet for the year before diagnosis [8] and usual
height and weight for each decade aged 20–60 yr. The interviewer took
anthropometric measurements using standardised methods and cali-
brated scales.
2.2.2. Vital status
Vital status was checked periodically over 14 yr from 2000 to 2014
(Fig. 1). Death information was provided monthly by Vital Statistics
Alberta (a legislated population-based registry) to the ACR with cause of
death from Statistics Canada. The time between actual death and
reporting to ACR was 3 mo on average. For men who left Alberta
postdiagnosis but remained in Canada, vital status linkages were made
with other provinces. For men not known to have died, annual linkage
with the Alberta Health registration ﬁle allowed for vital status
determination when last residing in Alberta. For men who left Alberta
and vital status was unknown by end of study, censoring time was the
date of leaving Alberta.
2.2.3. Postdiagnosis lifestyle
Postdiagnosis activity was measured up to three times per participant
(Fig. 1) on average 2.5, 4.7, and 6.8 yr postdiagnosis. At ﬁrst follow-up, in-
person interviews assessed activity undertaken since the prediagnosis
activity interview using the LTPAQ modiﬁed for a shorter time frame.
Cases reported diet, smoking, alcohol, and comorbidities using the same
questions as at diagnosis. Anthropometric measurements were taken. In
the second follow-up, physical activity since ﬁrst follow-upwas assessed
using a mailed version of the LTPAQ that we developed and validated [9]
to capture the past 1–2 yr of activity. Similarly, a third follow-up was
completed by mail, querying time since last follow-up.
2.2.4. Chart abstractions
In 2002 the ﬁrst medical chart review was completed and data
abstracted on staging, treatments, vital status, comorbidities, non-PCa
diagnoses, and recurrences/progressions. Recurrence was deﬁned as
further disease, identiﬁed through prostate-speciﬁc antigen (PSA)
changes and secondary treatments, following a signiﬁcant disease-free
period. Recurrence date was when second-line treatment began or a
decision was made not to treat. Progression occurred if PSA did not drop
to undetectable levels following radical prostatectomy, if a patient’s
condition became progressively worse, if treatment produced no
positive results, or if distant metastases at diagnosis became clinically
stable and then progressed. Progression date was when increased/
abnormal PSA was recorded or other diagnostic testing indicated
progression. Charts were sought from ACB treatment centres and, if
necessary, attending physicians. Chart abstractions were performed by
ACR health record technicians with no access to physical activity data;
TNM staging followed American Joint Committee on Cancer guidelines
[10], and interrater reliability of abstraction was assessed. Two
additional abstractions were completed in 2008 and 2014. Personalised
letters were mailed to physicians or a health record technician made
ofﬁce visits to obtain missing chart information.
2.3. Statistical analysis
The Compendium of Physical Activities [11] was used to assign
metabolic equivalent (MET) values to each self-reported activity.
Individual total physical activity was estimated as the sum of
[(Fig._1)TD$FIG]
Fig. 1 – Study timeline for the Prostate Cohort Study, Alberta, Canada, 1997–2014. The number of deaths is indicated for 830 men with prostate cancer
who completed the first physical activity follow-up interview.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 5 7 6 – 5 8 5578nonsedentary occupational, household, and recreational activities.
Vigorous activity was deﬁned by a MET value 6 and occupational
sedentary behaviour by a MET value 1.5. Sample size was predeter-
mined from our case-control study [6].
Three survival outcomes—all-cause mortality, PCa-speciﬁc mortality
(cause of death: ‘‘prostate gland’’), and ﬁrst recurrence/progression—
were assessed over time by activity quartile using Kaplan-Meier survival
curves and log-rank tests. Cox proportional hazards (PH) models were
used to compute hazard ratios (HRs), treating pre- or postdiagnosis
activity (in quartiles) as the exposure (linear tests for trend were
conﬁrmed by ﬁtting restricted cubic splines in multivariable survival
models [12] before categorising activity into quartiles [13]). The PH
assumption was evaluated by including an interaction term betweeneach activity variable and follow-up time. Fine and Gray competing risk
Cox survival analyses were used [14] to assess PCa-speciﬁc mortality.
Prediagnosis activity was derived from our lifetime questionnaire
[7]. Postdiagnosis activity was a time-weighted average of up to three
follow-up measures with missing follow-ups excluded (eg, if follow-ups
2 and 3 were missing, follow-up 1 was used). Participants with ﬁrst
recurrence/progression preceding follow-up 1 were excluded from
recurrence/progression models. We also jointly modelled postdiagnosis
activity and survival data using the JM R package (R Foundation for
Statistical Computing, Vienna, Austria; http://www.R-project.org) [15]
where observed longitudinal activity at all follow-ups was explicitly
modelled. Because results were similar between joint and Cox PH
models, we provide only Cox PH model results.
Table 1 – Participant characteristics (1997–2000) and physical activity levels after prostate cancer diagnosis in the Prostate Cohort Study,
Alberta, Canada, 1997–2014
Characteristics All participants All deaths PCa deaths First recurrence/progressiony
No. of participants 830 458 170 239
Race (n, %)
White 789 (95) 440 (96) 160 (94) 221 (92)
Other 41 (4.9) 18 (3.9) 10 (5.9) 18 (7.5)
Current married (n, %) 699 (84) 377 (82) 141 (83) 208 (87)
Educational level (n, %)
Less than high school 258 (31) 170 (37) 62 (36) 69 (29)
High school diploma 87 (11) 40 (8.7) 12 (7.1) 26 (11)
Trade certiﬁcate 170 (20) 97 (21) 36 (21) 56 (23)
Other nonuniversity 172 (21) 81 (18) 33 (19) 52 (22)
University 143 (17) 70 (15) 27 (16) 36 (15)
Overall stage (n, %) [10]
II (T1/T2, N0, M0) 642 (77) 327 (71) 98 (58) 168 (70)
III (T3, N0, M0) 57 (6.9) 24 (5.2) 9 (5.3) 16 (6.7)
III or IV (T3, NX, MX) 76 (9.2) 57 (12) 27 (16) 31 (13)
IV 55 (6.6) 50 (11) 36 (21) 24 (10)
T4, N0, M0 1 (1.7) 0 (0) 0 (0) 1 (4.0)
T4, N0/NX, M0/MX 5 (8.6) 4 (7.7) 1 (2.7) 2 (8.0)
Any T, N1, M0/MX 17 (31) 15 (30) 12 (33) 8 (32)
Any T, any N, M1 33 (60) 31 (62) 23 (64) 14 (56)
Any T, NX, MX 2 (3.4) 2 (3.8) 0 (0) 0 (0)
Gleason score (n, %)
<7 317 (38) 152 (33) 29 (17) 68 (28)
7 356 (43) 190 (42) 68 (40) 110 (46)
>7 157 (19) 116 (25) 73 (43) 61 (26)
Primary treatment (n, %)*
Prostatectomy 245 (30) 68 (15) 20 (12) 52 (22)
Radiation therapy 366 (44) 221 (48) 74 (44) 120 (50)
Hormone therapy** 527 (63) 335 (73) 145 (85) 172 (72)
First-degree relative history of PCa (n, %) 168 (20) 88 (19) 39 (23) 52 (22)
Heart disease (n, %) 161 (19) 105 (23) 27 (16) 42 (18)
High blood pressure (n, %) 271 (33) 169 (37) 59 (35) 79 (33)
Other chronic disease (n, %) 402 (48) 245 (53) 84 (49) 115 (48)
Smoking status (n, %)
Never smoker 241 (29) 119 (26) 56 (33) 64 (27)
Occasional smoker 6 (0.7) 2 (0.4) 0 (0) 3 (1.3)
Former occasional smoker 29 (3.5) 14 (3.1) 6 (3.5) 13 (5.4)
Former smoker 444 (53) 245 (53) 84 (49) 128 (54)
Current smoker 110 (13) 78 (17) 24 (14) 31 (13)
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
Age at diagnosis, yr 68 (62, 73) 71 (65, 75) 69 (63, 74) 68 (63, 73)
Body mass index, kg/m2 27.7 (25.4, 30.3) 27.6 (25.4, 30.4) 28.0 (25.4, 30.8) 27.7 (25.4, 30.4)
Dietary caloric intake, kcal/d 2012 (1644, 2475) 1986 (1614, 2452) 2044 (1733, 2553) 2038 (1692, 2520)
Total lifetime alcohol intake, g/wk 37 (12, 85) 39 (12, 88) 44 (13, 105) 42 (14, 86)
Prediagnosis physical activity, MET-h/wk per year
Total 144 (98, 198) 151 (104, 207) 147 (94, 210) 146 (94, 206)
Recreational 12.4 (6.6, 21.3) 10.8 (5.7, 19.4) 10.9 (6.5, 18.8) 12.1 (6.4, 21.6)
Nonsedentary occupational 107.3 (58.0, 159.5) 114.6 (66.7, 168.7) 102.9 (55.1, 176.3) 108.8 (52.3, 163.4)
Household 17.8 (9.0, 30.0) 17.9 (8.2, 30.6) 17.2 (8.6, 27.8) 18.6 (10.8, 30.2)
Prediagnosis vigorous physical activity, h/wk
per year
5.3 (1.8, 11.5) 5.5 (1.8, 12.3) 4.8 (1.7, 13.2) 5.5 (2.2, 12.2)
Prediagnosis occupational sedentary
behaviour, h/wk per year
4.5 (0.1, 12.8) 3.7 (0.0, 11.9) 3.6 (0.0, 12.1) 4.6 (0.0, 12.8)
Postdiagnosis physical activity, MET-h/wk per year
Total 74 (42, 119) 61 (31, 98) 75 (36, 107) 80 (49, 125)
Recreational 12.8 (4.1, 26.5) 9.7 (2.5, 21.1) 9.6 (2.0, 21.8) 10.8 (3.6, 26.8)
Nonsedentary occupational 5.2 (0.0, 40.9) 0.0 (0.0, 24.0) 5.9 (0.0, 38.6) 6.4 (0.0, 46.2)
Household 29.6 (15.1, 52.2) 28.8 (13.5, 52.5) 31.1 (14.9, 56.0) 33.3 (17.5, 54.0)
Postdiagnosis vigorous activity, h/wk per year 0.0 (0.0, 1.6) 0.0 (0.0, 0.6) 0.0 (0.0, 0.7) 0.0 (0.0, 1.8)
Postdiagnosis occupational sedentary
behaviour, h/wk per year
0.0 (0.0, 2.9) 0.0 (0.0, 1.5) 0.0 (0.0, 1.8) 0.0 (0.0, 2.4)
MET = metabolic equivalent; PCa = prostate cancer; Q = quartile.
Values are n (%) or median (quartile 1, quartile 3).
y First recurrence or progression; based on 723 cases (of 830) still at risk for ﬁrst recurrence/progression at the time of the ﬁrst postdiagnosis physical
activity follow-up.
* Participants could have more than one treatment.
** Included bilateral orchiectomy, luteinising hormone-releasing hormone agonists, nonsteroidal antiandrogens, steroidal antiandrogens.
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prediagnosis activity (for postdiagnosis models) were forced into Cox PH
models as covariates. Putative ones, namely, clinical Gleason score,
diagnostic PSA, baseline comorbidity, ﬁrst-degree relative PCa, body
mass index (BMI), body weight, and variables with unknown prognostic
value (marital status, education, ethnicity, residence (urban/rural),
number of prediagnosis digital rectal examinations, and PSA measure-
ments) and for all-cause mortality (prediagnosis alcohol and caloric
intake) were removed sequentially based on statistical nonsigniﬁcance.
For postdiagnosis activity analyses, we also assessed postdiagnosis
smoking, body weight, caloric and alcohol intake, and comorbidities. We
assessed interactions between physical activity and stage, hormone
therapy, prostatectomy, radiation therapy, Gleason score, age, and BMITable 2 – All-cause and prostate cancer (PCa)–specific mortality in rela
Study, Alberta, Canada, 1997–2014
Quartiles of postdiagnosis physical activity All-cause deaths/
cases
M
Total physical activity, MET-h/wk per year
42 158/207
>42 to 73 116/208
>73 to 119 109/207
>119 75/208
p value for trend
Recreational physical activity, MET-h/wk per year
4 144/207
>4 to 13 123/208
>13 to 26 99/208
>26 92/207
p value for trend
Nonsedentary occupational physical activity, MET-h/wk per year
0 231/337
>0 to 16 84/162
>16 to 53 84/163
>53 59/168
p value for trend
Household physical activity, MET-h/wk per year
15 132/208
>15 to 30 107/207
>30 to 52 101/207
>52 118/208
p value for trend
Vigorous physical activity, h/wk per year
0 299/457
>0 to 1.0 59/123
1.0–3.5 59/124
>3.5 41/126
p value for trend
Occupational sedentary behaviour, h/wk per year
0 308/482
>0 to 2.4 55/114
2.4–7.9 58/115
>7.9 37/119
p value for trend
CI = conﬁdence interval; HR = hazard ratio; MET = metabolic equivalent; PCa = pr
§ For 830 men who lived at least 2 yr after diagnosis of PCa.
y Estimates for total physical activity were adjusted for age at diagnosis, overall st
therapy), Gleason score, PSA level, region (urban vs rural), number of times had PSA
postdiagnosis total pack-years of smoking, prediagnosis total physical activity, pos
recurrence/progression of PCa. Models of each subtype of activity were further adju
the models were mutually adjusted for nonvigourous activity or nonsedentary beh
speciﬁed.
z Estimates for total physical activity were adjusted for age at diagnosis, overall sta
therapy), Gleason score, region (urban vs rural), number of times had PSA test done
comorbidity (Charlson Comorbidity Score), and time to any ﬁrst recurrence or prog
other types of activity; for vigorous activity or sedentary behaviour, the models we
respectively. Variables were treated as continuous unless otherwise speciﬁed. For t
the Fine and Gray method [12]; deaths from other causes constituted the competinat diagnosis (continuous) by entering their cross products into
multivariable Cox PH models.
All analyses were repeated to assess activity change (deﬁned using
pre- and postdiagnosis activity tertiles) over the diagnostic period. All
tests for statistical signiﬁcance were based on two-sided Wald tests.
Analyses were performed using SAS v.9.2 (SAS Institute, Cary, NC, USA)
and R v.3.0 [16].
3. Results
Of 988 cases in the case-control study [6], one was an
ineligible cancer and 830 participated in the first follow-uption to physical activity postdiagnosis§ of PCa in the Prostate Cohort
ultivariable adjusted
HR (95% CI)y
PCa deaths/
cases
Multivariable adjusted
HR (95% CI)z
1.0 49/207 1.0
0.72 (0.560.93) 34/208 0.66 (0.421.05)
0.74 (0.570.97) 53/207 1.02 (0.641.61)
0.58 (0.420.79) 34/208 0.65 (0.371.13)
<0.01 0.4
1.0 57/207 1.0
0.79 (0.611.02) 45/208 0.74 (0.491.12)
0.65 (0.500.85) 34/208 0.61 (0.390.95)
0.64 (0.480.84) 34/207 0.56 (0.350.90)
<0.01 0.01
1.0 71/337 1.0
0.84 (0.651.09) 28/162 0.91 (0.591.40)
0.98 (0.751.28) 38/163 1.12 (0.711.77)
0.65 (0.470.91) 33/168 0.90 (0.531.55)
0.04 0.9
1.0 43/208 1.0
0.72 (0.550.93) 36/207 0.73 (0.461.17)
0.72 (0.550.95) 40/207 0.90 (0.571.40)
0.89 (0.691.16) 51/208 1.04 (0.671.63)
0.5 0.6
1.0 111/457 1.0
0.68 (0.510.90) 19/123 0.68 (0.411.12)
0.86 (0.641.15) 19/124 0.70 (0.421.16)
0.65 (0.460.92) 21/126 0.73 (0.451.20)
0.01 0.09
1.0 111/482 1.0
0.72 (0.540.98) 20/114 0.67 (0.401.11)
0.96 (0.721.29) 22/115 0.94 (0.591.52)
0.72 (0.501.05) 17/119 0.66 (0.371.18)
0.11 0.19
ostate cancer; PSA = prostate-speciﬁc antigen.
age (II, III, III/IV, IV), treatment (prostatectomy, radiation therapy, hormone
test done (never/once/twice or more), total pack-years of smoking at diagnosis,
tdiagnosis comorbidity (Charlson Comorbidity Score), and time to any ﬁrst
sted for the other types of activity; for vigorous activity or sedentary behaviour,
aviour, respectively. Variables were treated as continuous unless otherwise
ge (II, III, III/IV, IV), treatment (prostatectomy, radiation therapy, and hormone
(never/once/twice or more), prediagnosis total physical activity, postdiagnosis
ression of PCa. Models of each subtype of activity were further adjusted for the
re mutually adjusted for nonvigorous activity or nonsedentary behaviour,
he outcome of PCa death, a competing risk survival analysis was used based on
g event.
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n = 16 poor health), participants on average had signifi-
cantly lower stage cancer and Gleason scores. Of 830 cases,
458 deaths and 170 PCa-specific deaths were identified up
to 2014. The leading cause of non-PCa death (n = 288) was
cardiovascular disease (48%). Of 723 men with no recur-
rence/progression before first postdiagnosis follow-up,
239 first recurrences/progressions were identified. Fol-
low-up was 100% for mortality and 96.5% for first
recurrences/progressions. Median time from diagnosis to
censoring/end of follow-up was 15.5 yr for survivors.
Median survival time was 14.1 yr; 5-yr survival was 88%.
The earliest death occurred 2.1 yr postdiagnosis. The
median time between final activity follow-up and death
was 3.0 yr (6 d to 12.7 yr) and for first recurrences/
progressions was 1.1 yr (same day to 9 yr). At baseline,
mean age was 67.3 yr, men were mainly overweight, 13%
were current smokers, and most had stage II cancer (77%)
(Table 1).
Multivariable-adjusted models revealed no consistent
associations between lifetime prediagnosis activity and any
outcome (Supplementary [1_TD$DIFF] ables 1–3). Postdiagnosis total
activity >119 versus 42 MET-hours/week per year was
associated with a 42% significantly lower risk of all-cause
mortality (Table 2) (p value for trend <0.01). Kaplan-Meier
curves were clearly differentiated between low versus high
quartiles showing survival benefit in the higher activity[(Fig._2)TD$FIG]Fig. 2 – Kaplan-Meier curves for postdiagnosis total physical activity in relation
Prostate Cohort Study, Alberta, Canada, 1997–2014.
MET = metabolic equivalent; Q = quartile.group approximately 5 yr postdiagnosis for all-cause
mortality (p < 0.001, log-rank test) and PCa-specific
mortality (p = 0.002, log-rank test) (Fig. 2). All-cause
mortality was significantly decreased in multivariable-
adjusted models by approximately 35% with more post-
diagnosis recreational activity (>13 vs 4 MET-hours/week
peryear;pvalue for trend<0.01), nonsedentaryoccupational
activity (>53vs0MET-hours/weekperyear;pvalue for trend
= 0.04), or vigorous activity >3.5 versus 0 hours/week per
year (p value for trend = 0.01) (Table 2). In a Fine and Gray
competing risk analysis [12], risk of PCa-specific deaths was
significantly decreased by approximately 40% comparing
>13 versus 4 MET-hours/week per year recreational
activity (p value for trend = 0.01) (Table 2). No convincing
interactions were found. Excluding men diagnosed with
distant metastasis or excluding men assessed within 12 mo
of death somewhat attenuated linear trends that were
statistically significant in primary analyses (Table 3), but
inverse associations remained. No consistent associations
were found between postdiagnosis activity and risk of first
recurrence/progression (Supplementary Table 4).
Survival was assessed across four patterns of activity
change. Crude/unadjusted relations with recreational ac-
tivity are depicted in Figure 3. The consistently active
subgroup (Supplementary Table 5), reporting>18–20MET-
hours/week per year recreational activity pre- and post-
diagnosis, experienced the highest overall survival startingto (A) all-cause mortality and (B) prostate cancer–specific death in the
Table 3 – Sensitivity analyses of statistically significant physical activity variables in the primary analysis,§ Prostate Cohort Study, Alberta,
Canada, 1997–2014
Quartiles of postdiagnosis physical activity All-cause deaths/
cases
Multivariable adjusted
HR (95% CI)y
PCa deaths/
Cases
Multivariable adjusted
HR (95% CI)z
Exclude 33 men with distant metastasis at diagnosis: n = 797
Total physical activity, MET-h/wk per year
42 147/199 1.0 40/199 1.0
>42 to 74 111/200 0.80 (0.621.03) 31/200 0.73 (0.451.19)
>74 to 119 101/199 0.77 (0.591.01) 47/199 1.09 (0.671.76)
>119 68/199 0.59 (0.420.81) 29/199 0.72 (0.401.29)
p value for trend <0.01 0.6
Recreational physical activity, MET-h/wk per year
4 135/199 1.0 48/199 1.0
>4 to 13 113/199 0.82 (0.631.07) 39/199 0.78 (0.501.24)
>13 to 27 93/199 0.69 (0.520.90) 29/199 0.65 (0.401.05)
>27 86/200 0.68 (0.500.91) 31/200 0.67 (0.411.09)
p value for trend <0.01 0.07
Nonsedentary occupational physical activity, MET-h/wk per year
0 217/322 1.0 61/322 1.0
>0 to 17 79/157 0.86 (0.661.13) 25/157 1.02 (0.641.61)
>17 to 54 79/157 0.94 (0.711.23) 33/157 1.12 (0.701.79
>54 52/161 0.62 (0.430.88) 28/161 0.94 (0.531.69)
p value for trend 0.02 1
Vigorous physical activity, h/wk per year
0 277/434 1.0 95/434 1.0
>0 to 1.0 57/120 0.68 (0.510.91) 17/120 0.67 (0.401.15)
1.0–3.5 53/118 0.82 (0.611.12) 14/118 0.62 (0.351.12)
>3.5 40/125 0.66 (0.470.94) 21/125 0.86 (0.521.42)
p value for trend 0.01 0.2
Exclude 68 physical activity assessments done within 12 mo of death: n = 804*
Total physical activity, MET-h/wk per year
42 148/201 1.0 42/201 1.0
>42 to 74 112/201 0.80 (0.621.04) 32/201 0.77 (0.481.23)
>74 to 118 105/201 0.81 (0.621.07) 51/201 1.23 (0.761.98)
>118 67/201 0.58 (0.420.81) 30/201 0.74 (0.411.32)
p value for trend <0.01 0.7
Recreational physical activity, MET-h/wk per year
4 137/201 1.0 54/201 1.0
>4 to 13 111/201 0.85 (0.661.10) 37/201 0.68 (0.441.07)
>13 to 27 97/201 0.72 (0.550.94) 31/201 0.59 (0.370.94)
>27 87/201 0.70 (0.520.94) 33/201 0.66 (0.421.06)
p value for trend 0.01 0.05
Nonsedentary occupational physical activity, MET-h/wk per year
0 220/326 1.0 65/326 1.0
>0 to 16 80/158 0.83 (0.641.10) 26/158 0.90 (0.581.41)
>16 to 53 79/158 0.94 (0.711.24) 34/158 1.12 (0.691.80)
>53 53/162 0.63 (0.450.90) 30/162 0.94 (0.541.66)
p value for trend 0.03 1
Vigorous physical activity, h/wk per year
0 249/385 1.0 87/385 1.0
>0 to 0.9 72/119 0.76 (0.581.00) 26/139 0.87 (0.561.36)
0.9–3.3 67/137 0.82 (0.621.09) 18/137 0.61 (0.351.06)
>3.3 44/143 0.70 (0.490.98) 24/143 0.83 (0.511.35)
p value for trend 0.02 0.18
CI = conﬁdence interval; HR = hazard ratio; MET = metabolic equivalent; PCa = prostate cancer; PSA = prostate-speciﬁc antigen.
§ For men who lived at least 2 yr after diagnosis of PCa.
y Estimates for total physical activity were adjusted for age at diagnosis, overall stage (II, III, III/IV, IV), treatment (prostatectomy, radiation therapy, hormone
therapy), Gleason score, PSA level, region (urban vs rural), number of times had PSA test done (never, once, twice or more), total pack-years of smoking at diagnosis,
postdiagnosis total pack-years of smoking, prediagnosis total physical activity, postdiagnosis comorbidity (Charlson Comorbidity Score), and time to any ﬁrst
recurrence/progression of PCa. Models of each subtype of activity were further adjusted for the other types of activity (recreational, household, occupational); for
vigorous activity the models were mutually adjusted for nonvigorous activity. Variables were treated as continuous unless otherwise speciﬁed.
z Estimates for total physical activity were adjusted for age at diagnosis, overall stage (II, III, III/IV, IV), treatment (prostatectomy, radiation therapy and hormone
therapy), Gleason score, region (urban vs rural), number of times had PSA test done (never, once, twice or more), prediagnosis total physical activity, postdiagnosis
comorbidity (Charlson Comorbidity Score), and time to any ﬁrst recurrence or progression of PCa. Models of each subtype of activity were further adjusted for the
other types of activity (recreational, household, occupational); for vigorous activity, the models were mutually adjusted for nonvigorous activity. Variables were
treated as continuous unless otherwise speciﬁed. For the outcome of PCa death, a competing risk survival analysis was used based on the Fine and Graymethod [12];
deaths from other causes constituted the competing event.
* n = 26 men had only one assessment.
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Fig. 3 – Kaplan-Meier survival curves for change in recreational physical activity from prediagnosis to postdiagnosis of prostate cancer (PCa) in relation
to (A) all-cause mortality and (B) PCa-specific mortality in the Prostate Cohort Study, Alberta, Canada, 1997–2014. Subgroups were defined based on
tertiles of average physical activity before and after diagnosis; high represents the highest tertile, and low-moderate represents the lowest and middle
tertiles (defined in Supplementary Table 5). Postdiagnosis activity represents average activity across follow-up questionnaires 1, 2, and 3 (for
participants who did not complete three assessments, the average was derived from one or two assessments).
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 5 7 6 – 5 8 5 5834–5 yr postdiagnosis, which was significantly higher than
for men remaining less active (HR: 0.66; 95% confidence
interval, 0.49–0.88) (Supplementary Table 6). Although the
consistently active subgroup also experienced the lowest
risk of PCa-specific mortality, risk was not statistically
significantly different from the consistently inactive sub-
group (Supplementary Table 6).
4. Discussion
Men diagnosed with stage II–IV PCa who survived at least
2 yr and reported higher total activity, occupational activity,
or vigorous activity experienced statistically significant
lower risks of all-causemortality over 15.5 yr. Postdiagnosis
recreational activitywas associatedwith significantly lower
risks of all-cause and PCa-specific mortality. Men who were
the most recreationally active before and after diagnosis
experienced the lowest risk of all-cause mortality (and PCa
mortality, although not statistically significant).
The inverse association between total activity and all-
cause mortality may have been influenced by cardiovascu-
lar deaths, which were prevalent in our study and others
[17,18] and are preventable with exercise [19]. We also
showed that men maintaining high recreational activitylevels pre- and postdiagnosis experienced the lowest all-
cause mortality rates. This finding, consistent with earlier
results [3], could inform prevention counselling of family
members, analogous to body weight [20,21] and smoking
[22] advice.We found no statistically significant association
with first recurrence/progression, unlike Richman et al who
assessed a similar outcome in T1–T2 cases [4]. The reasons
for discrepancy are unclear but may include different
definitions of cancer progression or different disease
profiles or treatments. The association with postdiagnosis
recreational activity was inverse, as with PCa-specific
mortality, but nonsignificant possibly because recurrence/
progression models were based on a subgroup of men
(n = 723).
Only recreational activity was associated with PCa-
specific deaths. Studies in humans and animals have shown
exercise to decrease risk of progression [4,23], and biologic
mechanisms are proposed [24–26]. Bonn et al [5] found that
PCa mortality was reduced with walking/bicycling or
exercise but not with housework or overall recreational
activity. Indirectly our findings implicate higher intensity
activity in PCa survival because high volumes of occupa-
tional and household (>52–53 MET-hours/week) activity
were not associated with risk of PCa death, whereas lower
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 5 7 6 – 5 8 5584volumes of recreational activity>13MET-hours/weekwere
associated with decreased risk. Yet the inverse association
we observed between PCa survival and vigorous activity did
not reach statistical significance, perhaps because few men
reported vigorous activity. In previous studies, significant
inverse trends were found between risk of progression and
walking pace [4], and risk of PCa death and vigorous
recreational activity [3]. In the latter study [3], a significant
58% risk reduction for PCa deaths was observed with
48 versus <3 MET-hours/week leisure-time activity (37%
of MET-hours were vigorous). A comparable analysis of our
data (Table 3) showed a nonsignificant 33–34% risk
reduction with >27 versus 4 MET-hours/week recrea-
tional activity (28% of MET-hours were vigorous). To our
knowledge, our study is the first to assess pre- and
postdiagnosis sedentary behaviour relative to PCa survival
and to show no statistically significant trend.
Relative to other studies [3,5], our longitudinal assess-
ment of all types and intensities of activity done pre- and
postdiagnosis, a long follow-up, high study power, and
measurement of sedentary behaviour are study strengths.
Limitations include possible misreporting of activity that
might have attenuated associations (particularly prediag-
nosis), a possible healthy worker effect in analysing
occupational activity, measuring sedentary behaviour only
in the occupational domain, and possible uncontrolled (or
imprecise control for) confounding, although numerous
lifestyle factors were assessed for model inclusion andwere
not statistically significant. Preexisting diabetes mellitus
and statin use, however, were not assessed. The generali-
sability of our findings is limited to mainly stage II cases,
patients aged <80 yr at diagnosis, and healthier patients
who survived at least 2 yr (because we excluded patients
unable to complete follow-up 1). Finally, reverse causation
may have occurred if questionnaires assessed the same 2-yr
period (approximately) when men experienced mortality-
related symptoms and therefore lowered their activity.
However, sensitivity analyses to assess this possibility
(Table 3) supported our primary results.
5. Conclusions
Physical activity is advised for PCa patients to alleviate
treatment-related side effects [27] and improve quality of
life [28], especially for patients receiving androgen-depri-
vation therapy [29]. Some authors have advised daily
physical activity and minimising sedentary behaviour
[30]. It is important to note, however, that very limited
epidemiologic evidence to date has investigated survival
outcomes in relation to these behaviours. Consequently,
findings from our study provide support for these emerging
recommendations and can inform a future exercise
intervention trial examining PCa outcomes.
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